Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to give your signed agreement to take part before any study procedures begin.
- You have been diagnosed with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, and it falls into one of these specific types: the cause is unknown (idiopathic); it runs in your family (heritable); it was caused by a drug or toxic substance; or it is linked to a connective tissue disease, HIV infection, a congenital heart condition (a heart problem present from birth), or high blood pressure related to liver disease.
- You were either diagnosed with PAH within the last 6 months, or you were diagnosed earlier but have been on a stable treatment plan for at least 3 months before joining the trial.
- Before joining, you had a specific heart test called a right heart catheterization that confirmed your PAH diagnosis by meeting certain pressure and resistance measurements in your heart and lungs (confirm with trial site for exact values).
Who may not be able to join:
- Before joining, you have a moderately severe breathing problem where your lungs have difficulty moving air out, based on specific breathing test results (confirm with trial site).
- Before joining, you have a severe restriction in your lung capacity, based on specific breathing test results (confirm with trial site).
- You were hospitalised for a serious worsening of right-sided heart failure within the week before joining the trial.
- You have more than moderate disease affecting the aortic or mitral valves in your heart.
- Within the past year, a heart scan showed that your heart's main pumping chamber is not working well enough (pumping less than 40% of its blood with each beat).
- You are currently pregnant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nadine Al-Naamani, MD, University of Pennsylvania
Phone: 215-294-9755
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Intake of food and nutrients; Epicardial adipose tissue (EAT) volume; Metabolomics; Right ventricular (RV) function; Adiponectin; Low lean mass; Accelerometry measures; Health-Related Quality of Life (HRQOL); Measurement of adiponectin levels pre- and post-exercise at baseline and at Week 12; Measurement of oxyhemoglobin and deoxyhemoglobin concentration pre and post- exercise at baseline and Week 12. Measurement of time to recovery of oxyhemglobin post-exercise at baseline and at Week 12.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.